Goodin Named 2022 Paul Parker Award Recipient
LEXINGTON, Ky. Susan Goodin, PharmD, FCCP, FASHP, BCOP (R198), senior director, CMC Leadership and Portfolio Strategy in BioTherapeutics Development & Supply of Janssen Pharmaceuticals, has been named the 2022 recipient of the Paul F. Parker Award. Goodin will receive the award at the American Society of Health-System Pharmacists (ASHP) Midyear Meeting in Las Vegas, Nevada.
The Paul F. Parker Award is a recognition of lifetime achievement given annually to a past resident of the University of Kentucky (UK) Pharmacy Residency Program or an individual intimately associated with the success of the program. This award recognizes an individual who has displayed a sustained contribution to the profession in practice, teaching, or research; a commitment to high ideals and excellence in their chosen field; leadership and innovation; and a passion for encouraging the personal and professional growth of others.
Goodin received her Bachelor of Science (’90) and Pharm.D. (’91) degrees from the University of Kentucky College of Pharmacy (UKCOP). She subsequently completed an American Society of Health-System Pharmacy accredited Pharmacy Practice Residency at the University of Kentucky Medical Center and an Oncology Pharmacy Residency at the Lucille P. Markey Cancer Center in conjunction with the University of Kentucky Medical Center. After completing her residencies, she joined the University of Medicine and Dentistry of New Jersey (Rutgers), where she was a founding member of the Cancer Institute of New Jersey and played a key leadership role in the organizational design and establishment of the clinical practice, clinical research infrastructure, and NCI-designation of the cancer center.
Goodin has demonstrated an unmatched ability to balance ground-breaking research and exceptional clinical care. During her 25 years at the cancer center, she continued to practice and conduct clinical trials while serving in various leadership roles in the university and the cancer center, including as the interim director of Rutgers Cancer Institute of New Jersey at University Hospital, deputy director of the Rutgers Cancer Institute in New Brunswick, a tenured professor at the Rutgers Robert Wood Johnson Medical School, the executive director of Statewide Affairs for the Rutgers Cancer Institute of New Jersey, and the executive officer for the Big Ten Cancer Research Consortium.
She served on the Editorial Board of the American Journal of Health-System Pharmacy, was the founding editor-in-chief of The Oncology Pharmacist and was a reviewer for several pharmacy and cancer journals. Goodin remains active in several national pharmacy organizations and previously served as the Board of Pharmacy Specialties and the Oncology Specialty Council chair. She is a past recipient of the ASHP Section of Clinical Specialists and Scientists Distinguished Service Award, the Cancer Institute of New Jersey Award of Hope for Patient Care, and the HOPA Award of Excellence. She has published more than 90 peer-reviewed articles on the treatment and prevention of cancer, demonstrating her leadership in practice and patient care.
“Dr. Goodin has given to Kentucky, and the world, her expansive and long-lasting contributions to oncology pharmacy resident and fellowship training, translational research through leading clinical trials, and an international reputation in cancer prevention and treatment research that is unmatched within pharmacy,” said David DeRemer, PharmD (R297), one of the nominators for the award.
The Parker Luncheon will be held at 11:30 a.m. on Tuesday, December 6, 2022, at Mandalay Bay in Las Vegas, NV. Click here to register for the luncheon.